Cochrane Evidence Synthesis and Methods ►

Atypical antipsychotics for autism spectrum disorder: a network meta-analysis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

Primary

To assess the comparative efficacy of atypical antipsychotics for irritability through network meta-analysis in children and adults with autism spectrum disorder (ASD).

Secondary

To assess the safety and efficacy of atypical antipsychotics as medications for core and non-core symptoms in children and adults with ASD.

This is a protocol.

Published:

3 May 2022

Authors:

Meza N, Rees R, Escobar Liquitay CM, Franco JVA, Sguassero Y, Williams K, Pringsheim T, Rojas V, Madrid E

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Meza N, ReesR, Escobar LiquitayCM, FrancoJVA, SguasseroY, WilliamsK, PringsheimT, RojasV, MadridE.Atypical antipsychotics for autism spectrum disorder: a network meta-analysis (Protocol). Cochrane Database of Systematic Reviews 2022, Issue 5. Art. No.: CD014965. DOI: 10.1002/14651858.CD014965.